Cardiovascular, mortality and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials by Kristensen, Soren L. et al.
  
 
 
 
 
Kristensen, S. L., Rorth, R., Jhund, P. S., Docherty, K., Sattar, N., Preiss, 
D., Kober, L., Petrie, M. C. and McMurray, J.J.V. (2019) Cardiovascular, mortality 
and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: 
a systematic review and meta-analysis of cardiovascular outcome trials. Lancet 
Diabetes and Endocrinology, 7(10), pp. 776-785. (doi:10.1016/S2213-
8587(19)30249-9) 
 
There may be differences between this version and the published version. You are 
advised to consult the publisher’s version if you wish to cite from it. 
 
 
 
http://eprints.gla.ac.uk/190412/ 
      
 
 
 
 
 
 
Deposited on: 16 July 2019 
 
 
 
 
 
 
 
 
 
 
Enlighten – Research publications by members of the University of Glasgow 
http://eprints.gla.ac.uk  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                             Elsevier Editorial System(tm) for The Lancet 
Diabetes & Endocrinology 
                                  Manuscript Draft 
 
 
Manuscript Number: THELANCETDE-D-19-00502R2 
 
Title: Cardiovascular, mortality and renal outcomes with glucagon-like 
peptide-1 receptor agonists in patients with type 2 diabetes - a 
systematic review and meta-analysis of randomised trials  
 
Article Type: Article (Original Research) 
 
Corresponding Author: Dr. John J. V. Mcmurray, BSc MB ChB MD 
 
Corresponding Author's Institution: BHF Glasgow Cardiovascular Research 
Centre, Faculty of Medicine - University of Glasgow 
 
First Author: Soren L Kristensen, MD 
 
Order of Authors: Soren L Kristensen, MD; Rasmus Rorth, MD; Pardeep S 
Jhund, PhD; Kieran Docherty, MBChB; Naveed Sattar, PhD; David Preiss, 
PhD; Lars Kober, MD; Mark C Petrie, MBChB; John J. V. Mcmurray, BSc MB 
ChB MD 
 
Manuscript Region of Origin: AFGHANISTAN 
 
Abstract: Background: Several glucagon-like peptide-1 (GLP-1) receptor 
agonists have been tested in clinical trials in patients with type 2 
diabetes with different patient populations, cardiovascular outcomes and 
duration of follow-up. We planned a systematic review and meta-analysis 
of these trials, examining cardiovascular death, atherothrombotic 
cardiovascular events, heart failure, and death from any cause, as well 
as renal and key safety outcomes.  
Methods: PubMed, Medline and the Cochrane central register of controlled 
trials were searched for eligible trials reporting major adverse 
cardiovascular events (MACE) i.e. cardiovascular death, stroke or 
myocardial infarction up to June 15, 2019. A meta-analysis was performed 
using a random-effects model to estimate overall hazard ratios (HR) for 
MACE, its components , death from any cause, hospital admission for heart 
failure, renal outcomes and key safety outcomes (severe hypoglycaemia, 
pancreatitis and pancreatic cancer). We also examined MACE in several 
patient subgroups based on patient population , glycated haemoglobin, 
trial duration, treatment dosing interval  and structural homology. 
Findings: Of 27 publications screened, 7 trials using GLP-1 receptor 
agonists, with a total of 56,006 patients, fulfilled the prespecified 
criteria and were included. Overall, GLP-1 receptor agonist treatment 
reduced MACE by 12% (HR 0.88; 95% CI 0.82, 0.94, p<0.001). There was no 
statistically significant heterogeneity across the subgroups examined.  
 
GLP-1 receptor agonist treatment reduced all-cause mortality by 12% 
(0.88; 0.83, 0.95, p=0.001), hospital admission for heart failure by 9% 
(0.91; 0.83, 0.99, p=0.028) and a broad renal composite by 17% (0.83; 
0.78, 0.89, p<0.001). There was no increase in risk of severe 
hypoglycaemia, pancreatitis or pancreatic cancer.  
Interpretation: GLP-1 receptor agonists reduced 3-component MACE, its 
individual components, all-cause mortality, risk of hospitalization for 
heart failure and worsening renal function (due mainly to reduction in 
urinary albumin excretion) in patients with type 2 diabetes.   There was 
no increase in risk of severe hypoglycaemia or pancreatic adverse 
effects. 
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ABSTRACT 1 
Background: Several glucagon-like peptide-1 (GLP-1) receptor agonists have been tested in 2 
clinical trials in patients with type 2 diabetes with different patient populations, cardiovascular 3 
outcomes and duration of follow-up. We planned a systematic review and meta-analysis of these 4 
trials, examining cardiovascular death, atherothrombotic cardiovascular events, heart failure, and 5 
death from any cause, as well as renal and key safety outcomes.  6 
Methods: PubMed, Medline and the Cochrane central register of controlled trials were searched for 7 
eligible trials reporting major adverse cardiovascular events (MACE) i.e. cardiovascular death, 8 
stroke or myocardial infarction up to June 15, 2019. A meta-analysis was performed using a 9 
random-effects model to estimate overall hazard ratios (HR) for MACE, its components , death 10 
from any cause, hospital admission for heart failure, renal outcomes and key safety outcomes 11 
(severe hypoglycaemia, pancreatitis and pancreatic cancer). We also examined MACE in several 12 
patient subgroups based on patient population , glycated haemoglobin, trial duration, treatment 13 
dosing interval  and structural homology. 14 
Findings: Of 27 publications screened, 7 trials using GLP-1 receptor agonists, with a total of 15 
56,006 patients, fulfilled the prespecified criteria and were included. Overall, GLP-1 receptor 16 
agonist treatment reduced MACE by 12% (HR 0.88; 95% CI 0.82, 0.94, p<0.001). There was no 17 
statistically significant heterogeneity across the subgroups examined.  18 
 19 
GLP-1 receptor agonist treatment reduced all-cause mortality by 12% (0.88; 0.83, 0.95, p=0.001), 20 
hospital admission for heart failure by 9% (0.91; 0.83, 0.99, p=0.028) and a broad renal composite 21 
by 17% (0.83; 0.78, 0.89, p<0.001). There was no increase in risk of severe hypoglycaemia, 22 
pancreatitis or pancreatic cancer.  23 
4 
 
Interpretation: GLP-1 receptor agonists reduced 3-component MACE, its individual components, 1 
all-cause mortality, risk of hospitalization for heart failure and worsening renal function (due 2 
mainly to reduction in urinary albumin excretion) in patients with type 2 diabetes.   There was no 3 
increase in risk of severe hypoglycaemia or pancreatic adverse effects.  4 
Funding: DP is supported by a University of Oxford BHF Centre of Research Excellence Senior 5 
Transition Fellowship (RE/13/1/30181). JJVMcM is supported by BHF Centre of Research 6 
Excellence award number RE/18/6/34217. 7 
Keywords: diabetes, GLP-1 receptor agonists, MACE, heart failure 8 
 9 
 10 
 11 
 12 
 13 
 14 
 15 
 16 
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RESEARCH IN CONTEXT 1 
Evidence before this study 2 
Glucagon-like peptide-1 (GLP-1) receptor agonists effectively decrease glycated haemoglobin (HbA1c) in 3 
patients with type 2 diabetes mellitus. A variety of agents of this class with differing structures and durations 4 
of action have been studied in randomised placebo-controlled trials of varying size and with different patient 5 
populations and effects on cardiovascular outcomes. In light of these differences, we conducted a meta-6 
analysis of all large placebo-controlled GLP-1 receptor agonist trials to obtain robust estimates on the effect 7 
of this class of agent on a range of cardiovascular and renal endpoints, and patient subgroups.  8 
Medline (via PubMed) and the Cochrane Controlled Register of Trials (up to 15 June 2019) were searched 9 
for trials comparing a GLP-1 receptor agonist to placebo in >500 patients and reporting a primary outcome 10 
including cardiovascular death, non-fatal myocardial infarction and non-fatal stroke using the search terms 11 
“glucagon-like peptide-1 receptor agonists”, “cardiovascular mortality”, “myocardial infarction”, “stroke” 12 
and “heart failure”, “exenatide”, “liraglutide”, “semaglutide”, “albiglutide”, “dulaglutide”, “placebo”, and 13 
“randomized clinical trial”. 7 trials were identified; ELIXA (lixisenatide), LEADER (liraglutide), SUSTAIN-14 
6 (semaglutide), EXSCEL (extended release exenatide), Harmony Outcomes (albiglutide), REWIND 15 
(dulaglutide) and PIONEER 6 (oral semaglutide).  16 
 17 
Added value of this study 18 
GLP-1 receptor agonists reduce all-cause mortality, the composite of cardiovascular death, myocardial 19 
infarction and stroke (MACE), each of the components of this outcome, hospital admission for heart failure 20 
and a composite renal outcome of worsening of estimated glomerular filtration rate (eGFR), end stage renal 21 
disease, death attributable to renal causes, or new onset macroalbuminuria (data not available in Harmony 22 
Outcomes and PIONEER 6 for the latter two outcomes). The benefit on MACE was consistent across all but 23 
one subgroup (with a suggestion of less effect of exendin 4 based compounds). The incidence of severe 24 
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hypoglycaemia, pancreatitis and pancreatic cancer did not differ between GLP-1 receptor agonist treatment 1 
and placebo. The present meta-analysis is the largest pooled study of the effect of GLP-1 RA on 2 
cardiovascular and renal outcomes in patients with type 2 diabetes mellitus. Furthermore, compared to 3 
previous meta-analyses, it includes a greater number of patients without established cardiovascular disease, a 4 
new agent within this class of glucose lowering agents (dulaglutide) and an oral formation of an agent 5 
previously only available as a subcutaneous injection (semaglutide).  6 
 7 
Implications of all the available evidence 8 
The cardioprotective effects of GLP-1 receptor agonists in patients with established cardiovascular disease 9 
and the reduction in risk of heart failure and worsening renal function represent an important treatment 10 
opportunity to reduce morbidity and mortality in patients with type 2 diabetes mellitus.  11 
 12 
 13 
  14 
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INTRODUCTION 1 
Prevention of non-fatal and fatal cardiovascular events is a key goal of the management of patients 2 
with type 2 diabetes mellitus.
1,2
  In addition to blood pressure and cholesterol-lowering therapies, 3 
two of the newer classes of anti-hyperglycaemic agents also reduce cardiovascular risk.  One of 4 
these, the glucagon-like peptide-1 (GLP-1) receptor agonists, decrease glycated haemoglobin 5 
(HbA1c) by stimulating glucose-dependent insulin secretion and by reducing glucagon secretion, 6 
gastric emptying and appetite.
3,4
  GLP-1 receptor agonists also lead to modest improvements in 7 
lipids, reductions in blood pressure and weight, and carry a low risk of hypoglycaemia.  Agents in 8 
this class, however, differ in structure and duration of action and have been studied in trials of 9 
varying size and with different patient populations and in individual trials the effects on 10 
cardiovascular outcomes have not been consistent.
5-15
  In view of this we conducted a meta-analysis 11 
of all the large placebo-controlled GLP-1 receptor agonist trials, to obtain robust estimates of the 12 
effect of this class of agents on different cardiovascular endpoints and patient subgroups. We have 13 
also examined renal outcomes and key safety endpoints. Such a systematic review is helpful in 14 
supporting guideline recommendations on use of glucose lowering therapies to reduce 15 
macrovascular and renal outcomes in adults with type 2 diabetes.
1,2
 16 
 17 
  18 
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METHODS 1 
Search strategy and study selection: We identified published randomised placebo-controlled trials 2 
(RCTs) testing GLP-1 receptor agonists in patients with type 2 diabetes (Appendix Table 1). Both 3 
injectable and oral agents were included. We further restricted the search to trials with a primary 4 
outcome including cardiovascular death, non-fatal myocardial infarction and non-fatal stroke. 5 
Medline (via PubMed), and the Cochrane Controlled Register of Trials (Up to 15 June 2019) was 6 
searched with the search terms including “glucagon-like peptide-1 receptor agonists”, 7 
“cardiovascular mortality”, “myocardial infarction”, “stroke” and “heart failure”, “exenatide”, 8 
“liraglutide”, “semaglutide”, “albiglutide”, “dulaglutide”, “placebo”, and “randomized clinical 9 
trial”. We restricted our search to trials including >500 patients. Included trials were assessed for 10 
bias using the Cochrane Risk of Bias Tool (Appendix Table 2). A Preferred Reporting Items for 11 
Systematic Reviews and Meta-analyses (PRISMA) flow chart detailing the selection process is 12 
presented in Figure 1.  13 
Data extraction: Data were extracted by SLK and RR, with conflicts over study inclusion resolved 14 
by consensus.  15 
Selection of outcomes: Cardiovascular outcomes of interest were major adverse cardiovascular 16 
events (MACE), a composite outcome comprised of cardiovascular death, myocardial infarction 17 
and stroke, each of the components of this outcome, hospital admission for heart failure and death 18 
from any cause. Renal and safety outcomes were also examined. Two renal outcomes were 19 
examined, as reported previously: a narrower composite consisting of worsening of estimated 20 
glomerular filtration rate (eGFR), and a broader one which included end-stage kidney disease, death 21 
due to kidney disease and new onset macroalbuminuria (Appendix Table 3). The four key safety 22 
outcomes of interest were severe hypoglycaemia, retinopathy, pancreatitis and pancreatic cancer 23 
9 
 
(Appendix Table 4). We also examined thyroid cancer (Appendix Table 5). In all 7 trials, local 1 
investigators were encouraged to manage participants in accordance with local guidelines (and 2 
could use most non-study glucose lowering treatments as desired). In 6 of the 7 trials, the mean 3 
between-treatment group difference in HbA1c was in the range 0.3% and 0.7%. We compared 4 
treatment effect in the following subgroups: primary versus secondary prevention, higher versus 5 
lower baseline HbA1c concentration (see footnote to Figure 3 for details), longer versus shorter 6 
duration of follow-up, drug-dosing daily versus weekly, human GLP-1 homology, body mass index 7 
<30 versus ≥30, age <65 years versus ≥65 years, baseline eGFR <60 vs ≥60 mL/min/m2. All 8 
outcomes were adjudicated with the exception of severe hypoglycaemia, and event definitions for 9 
each trial are listed in the Appendix (Tables 1,3,4). 10 
 11 
Data analysis: Summary statistics from the individual trials included were used, as individual level 12 
data were not available. HRs and 95% CIs from the trial papers, supplementary appendix or 13 
secondary publications were used. Estimates from each study were combined by use of inverse 14 
variance-weighted averages of logarithmic hazard ratios (HR) in random-effects analysis. Inter-15 
study heterogeneity was assessed using the I
2 
index and Cochran´s Q test. I
2
 index values lower than 16 
25% indicated low, 26-50% moderate and more than 50% high degree of heterogeneity, and 17 
Cochran´s Q statistic p<0.05 were considered indicators for significant heterogeneity. Number 18 
needed to treat (NNT) was calculated using the method of Altman and Andersen, and median 19 
duration of follow-up was estimated by a weighted average.
16
.  The fragility index, the minimum 20 
number of events needing to change from a non-event to an event in order to render a significant 21 
result non-significant, was calculated for 3-component MACE outcomes using the method 22 
described by Walsh et al. (Appendix Table 6).
17
 Interactions between treatment and subgroups were 23 
10 
 
examined using a test for heterogeneity, using p<0.1 as significant. All analyses were performed 1 
separately using Stata version 14 (Stata Corp. College Station, Texas, USA).  2 
 3 
Role of the funding source: The study was planned and conducted by members of the Metabolic 4 
and Diabetes Research Group and Heart Failure research Group at the University of Glasgow 5 
(KFD, PSJ, MCP, NS and JJVMcM), the Department of Cardiology, Rigshospitalet University 6 
Hospital, Copenhagen (SLK, RR, LK) and the Nuffield Department of Public Health at the 7 
University of Oxford (DP) using institutional funds. No external funder was involved in the study.  8 
 9 
10 
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RESULTS 1 
 2 
Of 27 articles screened for eligibility, 7 trials with 56,006 patients were included in the meta-3 
analysis (Figure 1). In order of reporting, these were: The Evaluation of Lixisenatide in Acute 4 
Coronary Syndrome (ELIXA), the Liraglutide Effect and Action in Diabetes: Evaluation of 5 
Cardiovascular Outcomes Results (LEADER), the preapproval Trial to Evaluate Cardiovascular and 6 
Other Long-term outcomes with Semaglutide in Subjects with Type 2 Diabetes (SUSTAIN-6), the 7 
Exenatide Study of Cardiovascular Event Lowering (EXSCEL), Albiglutide and cardiovascular 8 
outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes), 9 
Researching Cardiovascular Events With a Weekly Incretin in Diabetes (REWIND), and a trial 10 
investigating the Cardiovascular Safety of Oral Semaglutide in Subjects with Type 2 Diabetes 11 
(PIONEER 6).
6-14
 All included trials were assessed for bias using the Cochrane risk of bias tool. 12 
The trials were assessed as high quality with a low risk of bias (Appendix, Table 2). The key trial 13 
and patient characteristics at baseline are presented in Tables 1 and Appendix Table 1.  14 
All trials were of substantial size (>3000 patients). ELIXA enrolled patients with a recent acute 15 
cardiovascular syndrome whereas all other trials included patients with stable cardiovascular 16 
disease, cardiovascular risk factors or both. All trials, except ELIXA, had MACE as the primary 17 
endpoint; in ELIXA an expanded composite including hospitalization for unstable angina was used. 18 
Lixisenatide (ELIXA), liraglutide (LEADER), and oral semaglutide (PIONEER 6) were each 19 
administered daily, whereas the remaining GLP-1 receptor agonists were administered once weekly. 20 
PIONEER 6 differed from the remaining trials in that semaglutide was taken orally, compared with 21 
subcutaneous administration of the treatments used in the remaining studies.  22 
12 
 
Mean age at baseline ranged from 60 years in ELIXA to 66 years in PIONEER 6 and REWIND. 1 
The highest proportion of women was included in REWIND (46% compared with between 31 and 2 
39% in the remaining trials). The proportion of patients with established cardiovascular disease at 3 
baseline ranged from 100% in ELIXA and Harmony Outcomes to 31% of those in REWIND (Table 4 
1). Kidney function was similar across trials (with median estimated glomerular filtration rate 5 
ranging from 74 to 80 ml/min/m
2
). Median HbA1c was lowest in REWIND and ELIXA (7.1% and 6 
7.7%, respectively) and highest, at 8.7%, in LEADER, SUSTAIN-6 and Harmony Outcomes. 7 
REWIND had the lowest proportional use of insulin at baseline (24% compared with 39-61% in 8 
remaining trials). The median length of follow-up ranged from 1.3 years in PIONEER 6 to 5.4 years 9 
in REWIND; the estimated median follow-up was 3.2 years (Appendix Table 1). Treatment 10 
discontinuation and loss to follow-up is summarised in Appendix Table 7. 11 
In the pooled analysis, treatment with a GLP-1 receptor agonist led to a 12% relative risk reduction 12 
in MACE (HR 0.88; 95% CI 0.82, 0.94; p<0.001) [Figure 2]. The NNT was 75 (95% CI 50, 151) 13 
over an estimated median follow-up of 3.2 years and the fragility index, overall, was 202 (Appendix 14 
Table 6). When assessing the components of the composite MACE endpoint separately, GLP-1 15 
receptor agonist use led to a reduction in risk of death from cardiovascular causes (HR 0.88 95% CI 16 
0.81, 0.96; p=0.001), fatal- or non-fatal stroke (HR 0.84; 95% CI 0.76, 0.93; p<0.001), and fatal or 17 
non-fatal MI (HR 0.91; 95% CI 0.84, 1.00; p=0.043) [Figure 2].  18 
In subgroup analyses there was no statistical heterogeneity between the effect of a GLP-1 receptor 19 
agonist in “primary prevention” patients (those without established cardiovascular disease) and 20 
those with cardiovascular disease at baseline: HR 0.95 (95% CI 0.83, 1.08) for “primary 21 
prevention” and 0.86 (0.79, 0.94) for “secondary prevention” , p for interaction=0.22. Similarly, we 22 
found no heterogeneity for the effect of GLP-1 receptor agonist therapy when examined by baseline 23 
HbA1c (“low” compared with “high” median HbA1c), shorter compared with longer trial follow-up 24 
13 
 
(<3 years vs. ≥3 years median follow-up), drug dosing interval (daily compared with weekly 1 
dosing), reflecting duration of drug action. The one possible exception was the comparison of 2 
exendin 4-based compounds (lixisenatide and exenatide) and agents more homologous with human 3 
GLP-1 (all other drugs studied);  this analysis suggested heterogeneity: HR 0.95 (95% CI 0.85, 4 
1.06) for exendin 4-based, compared with 0.84 (0.79, 0.90) for GLP-1-based, p-value for 5 
interaction=0.06 (Figure 3). 6 
Compared with placebo, treatment with a GLP-1 receptor agonist reduced the risk of death from 7 
any cause by 12% (HR 0.88; 95% CI 0.83, 0.95; p=0.001), giving a NNT of 108 (77, 260) [Figure 8 
4]. 9 
The risk of HF hospitalization was also reduced in GLP-1 receptor agonist treated patients, by 9% 10 
(HR 0.91; 95% CI 0.83, 0.99; p=0.028), giving a NNT of 311 (164, 2797) [Figure 4]. 11 
Renal events were not available for Harmony Outcomes or PIONEER 6. Treatment with a GLP-1 12 
receptor agonist reduced the broader composite renal outcome of worsening renal function, end-13 
stage renal disease and renal death, including development of macroalbuminuria, by 17% (HR 0.83, 14 
95% CI 0.78, 0.89) with a NNT of 62 (48, 96). There was a 13% reduction (HR 0.87, 0.73, 1.03) in 15 
the narrower worsening renal function outcome which was of borderline statistical significance; the 16 
corresponding NNT was 245 (118, -1064) (Figure 4). 17 
The incidence of severe hypoglycaemia, pancreatitis and pancreatic cancer did not differ between 18 
GLP-1 receptor agonist treatment and placebo (Appendix Figure 1). The incidence of retinopathy 19 
did not differ between GLP-1 receptor agonist treated and placebo treated patients, but this outcome 20 
was not defined consistently among the trials (Appendix Figure 1). The rate of thyroid carcinoma 21 
was low and did not differ between the active treatment and placebo groups (Appendix Table 5). 22 
14 
 
  1 
15 
 
DISCUSSION 1 
The present meta-analysis includes 13,084 (30%) more patients, 1394 (29%) more MACE 2 
endpoints, 1818 (95%) more renal events and approximately 56,000 more years of patient exposure 3 
than the largest prior study of this type.
18,19
 The present report also includes 6709 (95%) more 4 
“primary prevention” patients (i.e. with cardiovascular risk factors rather than established 5 
cardiovascular disease), one additional agent in the class i.e. dulaglutide with homology to human 6 
GLP-1 and a long duration of action, and a novel oral formulation of semaglutide which was 7 
administered by sub-cutaneous injection in a previous trial.  8 
 9 
Three-component MACE, the primary endpoint in 6 of the 7 trials, was reduced by 12%, reflecting 10 
a beneficial effect on death from cardiovascular causes (relative risk reduction 12%), as well as a 11 
reduction in risk of stroke (16% relative risk-reduction in fatal and non-fatal stroke).  The reduction 12 
in myocardial infarction (9% relative risk-reduction in fatal and non-fatal myocardial infarction) 13 
was less robust though directionally concordant. The NNT for MACE was 75 (95% CI 50, 151) 14 
over an estimated median duration of follow-up of 3.2 years. The relative risk reduction in MACE 15 
in a recent sodium-glucose co-transporter 2 (SGLT2) inhibitor meta-analysis was 11 (4-17)% and 16 
the NNT 97 (63, 266) over an estimated median follow-up of 3.3 years, although this comparison 17 
should be made cautiously as it does not take account of differences in the patient populations 18 
studied.. The hazard ratio for death from any cause in GLP-1 receptor agonist trials was 0.88 (95% 19 
CI 0.83-0.95) and NNT 108 (77, 260); in the SGLT2 inhibitor meta-analysis the corresponding HR 20 
was 0.85 (95% CI 0.78-0.93) and NNT 101 (69,216).
20
   21 
  22 
 23 
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We undertook several subgroup analyses to address the explanations proposed for the different 1 
effects on cardiovascular outcomes observed among the various GLP-1 receptor agonist trials. 2 
These include differences in the specific molecule tested, in the patients randomized, and in the 3 
duration of follow-up. Albiglutide, dulaglutide, liraglutide, and semaglutide are more similar, 4 
structurally, to native GLP-1 whereas exenatide and lixisenatide are based, structurally, on exendin-5 
4.
21,22
 Duration of treatment effect also differs markedly between the agents studied, although this 6 
does not reflect structural homology, with some GLP-1 receptor agonists of each type having a 7 
short pharmacologic half-life (e.g. lixisenatide 2-3 hours and liraglutide 12 hours) and others a long 8 
half-life (e.g. dulaglutide 120 hours and subcutaneous semaglutide 170 hours), or available as a 9 
sustained release formulation (exenatide), reflected in daily versus weekly dosing.
23
 The oral 10 
formulation of semaglutide used in PIONEER 6 required daily dosing. With the seven trials now 11 
available it was possible to examine whether these pharmacological characteristics, and their 12 
permutations, influence treatment efficacy. While duration of drug action did not seem to modify 13 
the treatment-effect, there was a suggestion of an interaction related to chemical structure, with a 14 
possibly smaller effect on MACE of agents based on exendin-4. This apparent interaction could be 15 
unduly influenced by ELIXA, which was unique in recruiting patients with a recent acute coronary 16 
syndrome (and also used a very short-acting agent, administered once daily), poor adherence in 17 
EXSCEL (40% permanent treatment discontinuation) or may be a chance finding. The ongoing 18 
Efpeglenatide on Cardiovascular Outcomes trail (AMPLITUDE-O - ClinicalTrials.gov unique 19 
identifier: NCT03496298), using a long-acting exendin-4 based GLP-1 receptor agonist in patients 20 
with established cardiovascular disease or cardiovascular risk factors will provide more evidence on 21 
this question. 22 
 23 
17 
 
The difference in patient population enrolled in the various GLP-1 receptor agonist trials has also 1 
been considered a potential explanation for the difference in outcomes among the studies.
24
 In 2 
particular, the lack of clear reduction in the primary MACE endpoint in EXSCEL has been 3 
attributed to the higher proportion of patients without established cardiovascular disease 4 
randomized in that trial, compared with the preceding GLP-1 receptor agonists trials. The inclusion 5 
of PIONEER 6 and, especially, REWIND allowed us to examine this question, with an almost 6 
doubling in the number of “primary-prevention” patients, overall, exposed to a GLP-1 receptor 7 
agonist, although even with this, the number of participants with MACE in this subgroup was less 8 
than a third of that in most other subgroups. Consequently, this analysis may still be under powered 9 
and, although there was no heterogeneity for the effect of GLP-1 receptor agonist treatment, the 10 
statistical test for interaction is weak. Therefore we cannot be certain that the relative risk reduction 11 
in “primary prevention” patients was the same as in “secondary prevention” patients and even if it 12 
was, the absolute risk reduction in the “primary prevention” population will be smaller, and the 13 
treatment likely to be less cost-effective, because individuals without established cardiovascular 14 
disease are at lower baseline risk than “secondary prevention” patients. These additional data may, 15 
therefore, not be sufficiently robust to challenge the new guideline recommendations only to use 16 
GLP-1 receptor agonists in patients with established cardiovascular disease.
1,2
   17 
 18 
Duration of follow-up was a further potential explanation for difference discrepancy in trial 19 
outcomes, with, for example, the much shorter follow-up in ELIXA (median 2.1 years) than 20 
LEADER (median 3.8 years) highlighted as an important difference between the first two large 21 
outcome trials with a GLP-1 receptor agonist. However, duration of follow-up did not seem to 22 
modify the benefit of treatment on the composite MACE outcome.  23 
18 
 
Two of the other subgroups merit discussion. The effect of GLP-1 receptor agonist treatment was 1 
consistent according to age and renal function. Because older age and lower eGFR were associated 2 
with higher rates of MACE, the absolute benefit was larger in these individuals.  3 
This updated meta-analysis also shows for the first time that treatment with a GLP-1 receptor 4 
agonist reduces the risk of heart failure hospitalization, although the reduction in risk was small in 5 
relative (9%, 95% CI 1-17%) and absolute (NNT 311; 95% CI 164, 2797) terms and was not 6 
statistically robust. This effect was also, clearly, much smaller than seen with SGLT2 inhibitors, 7 
which showed a relative risk reduction of 31 (21-39)% and a NNT of 100 (79, 147) over a similar 8 
median duration of follow-up (3.2 vs 3.3 years). Nevertheless, a GLP-1 receptor agonist may be an  9 
alternative in a patient with heart failure (or renal impairment) who cannot take a SGLT2 10 
inhibitor.
20
 The explanation for why GLP-1 receptor agonists should reduce this endpoint is not 11 
clear, especially as these agents has not demonstrated any benefit in trials in patients with 12 
established heart failure with reduced ejection fraction.
25,26
 One possibility is that this favourable 13 
effect in the meta-analysis is secondary to reduction in myocardial infarction, a common precursor 14 
of heart failure. In this context, is notable that the largest reductions in heart failure were in the two 15 
trials (Harmony Outcomes and LEADER) with the greatest reduction in myocardial infarction. This 16 
hypothesis, however, needs further investigation, for example with examination of the time 17 
sequence of cardiovascular events in individual patients.  18 
 19 
It is clear, overall, that GLP-1 receptor agonists are cardioprotective agents. The time course of their 20 
effects, apparent in the individual trials, and the types of cardiovascular events prevented suggest 21 
that GLP-1 receptor agonists have primarily an anti-atherothrombotic effect.  This profile is distinct 22 
from the SGLT 2 inhibitors which exhibit an effect much more rapidly and which is more 23 
19 
 
pronounced on heart failure, raising the possibility of therapeutic synergy from the combination of 1 
these two classes of drug.
27
   2 
 3 
This may also be true for renal outcomes. While we found that GLP-1 receptor agonists clearly 4 
reduced the risk of worsening of kidney function when assessed using a composite outcome driven 5 
by an increase in urinary albumin excretion, the benefit on a composite including a significant 6 
decline in eGFR (or increase in creatinine) was less clear, of borderline statistical significance and 7 
not as pronounced as seen with SGLT2 inhibitors.
18,27 
The relative risk reduction in the “harder” 8 
renal endpoint in the three large, broadly inclusive, SGLT2 inhibitor trials was 45 (36-52)% with a 9 
NNT of 79 (69, 99), compared with 13 (27-+3)% and 245 (118, -1064) in the present meta-10 
analysis.
18
 11 
 12 
Lastly, this meta-analysis suggests that prior concerns about pancreatitis and pancreatic cancer with 13 
GLP-1 receptor agonists seem unfounded and there was also no increase in risk of severe 14 
hypoglycaemia. We also so no overall increase in adverse eye-outcomes, although these were 15 
inconsistently defined in the trials, a deficit that should be remedied in future studies. The outcomes 16 
reported did not require systematic eye examination and this too is required for a full understanding 17 
of the effect of any glucose-lowering therapy on eye health. A dedicated trial of this type is 18 
currently underway with semaglutide (FOCUS - ClinicalTrials.gov unique identifier: 19 
NCT03811561). Our study has other limitations, including lack of patient-level data, restriction of 20 
subgroup analyses to the primary 3-component MACE endpoint, and ability to examine only the 21 
secondary endpoints and adverse events of special interest reported by the investigators of the trials 22 
included. 23 
 24 
20 
 
In conclusion, in this meta-analysis, we show that in patients with type 2 diabetes, GLP-1 receptor 1 
agonists reduced 3-component MACE, its individual components of, all-cause mortality and risk of 2 
hospitalization for heart failure.   Treatment with a GLP-1 receptor agonist also reduces the risk of 3 
worsening renal function, due mainly to a decrease in development of macroalbuminuria. These 4 
benefits were obtained without an increase in risk of severe hypoglycaemia, pancreatic adverse 5 
effects, or thyroid cancer. 6 
 7 
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Table 1: Baseline characteristics and use of glucose lowering agents across trials 
25 
 
 ELIXA 
n=6068 
LEADER 
n=9340 
SUSTAIN-6 
n=3297 
EXSCEL 
n=14752 
HARMONY 
n=9463 
REWIND 
n=9903 
PIONEER 6 
n=3183 
Drug studied  Lixisenatide Liraglutide Semaglutide Exenatide Albiglutide Dulaglutide Semaglutide 
Structural basis Exendin-4 based Human GLP-1 
based 
Human GLP-1 
based 
Exendin-4 based Human GLP-1 
based 
Human GLP-1 
based 
Human GLP-1 
based 
Administration route subcutaneous subcutaneous subcutaneous subcutaneous subcutaneous subcutaneous oral 
Dose 20 ug/day 1.8 mg/day 0.5 or 1 mg/week 2 mg/week 30 or 50 mg/week 1.5 mg/week 14 mg/day 
Age, mean – years  60±10 64±7 65±7 62±9 64±7 66±7 66±7 
Female sex, no. (%) 1861 (31%) 3337 (36%) 1295 (39%) 5603 (38%) 2894 (31%) 4589 (46%) 1007 (32%) 
BMI (kg/m
2
) 30.1±5.6 32.5±6.3 32.8±6.2 32.7±6.4 32.3±5.9 32.3±5.7 32.3±6.5 
Caucasian 4576 (75%) 7238 (78%) 2736 (83%) 11175 (76%) 6583 (70%) 7498 (76%) 2300 (72%) 
Diabetes duration, years 9.2±8.2 12.8±8.0 13.9±8.1 13.1±8.3 14.2±8.8 10.6±7.2 14.9±8.5 
HbA1c (%) 7.7±1.3 8.7±1.6 8.7±1.5 8.1±1.0 8.7±1.5 7.3±1.1 8.2±1.6 
Proportion with CVD 6068 (100%) 7598 (81%) 2735 (83%) 11175 (76%) 6678 (71%) 3114 (31%) 2692 (85%) 
Proportion with HF 1358 (22%) 1667 (18%) 777 (24%) 2389 (16%) 1922 (20%) 852 (9%) 388 (12%) 
Systolic blood pressure 
(mmHg) 
129±17 136±18 136±17 135±17 135±17 137±17 136±18 
eGFR, mL/min per 1.73 m
2 
78±21 80 (SD not given) 80 (61, 92) 77 (61,92) 79±25 75±24  74±21 
Glucose lowering agents. (%)        
Insulin  2374 (39%) 4159 (45%) 1913 (58%) 6838 (46%) 5597 (59%) 2398 (24%) 1943 (61%) 
Biguanides 4021 (66%) 7136 (76%) 2414 (73%) 11295 (77%) 7970 (84%) 8016 (81%) 2437 (77%) 
Sulfonylurea 2004 (33%) 4721 (51%) 1410 (43%) 5401 (37%) 2725 (29%) 5644 (57%) 1007 (32%) 
Thiazolidinedione 95 (2%) 573 (6%) 76 (2%) 579 (4%) 194 (2%) 168 (2%) N/A 
DPP4-inhibitor NA 6 (<1%) 5 (<1%) 2203 (15%) 1437 (15%) 88 (1%) 0 
SGLT2 inhibitor NA NA 5 (<1%) 77 (1%) 575 (6%) 12 (0%) 301 (10%) 
 BMI – body mass index, HbA1c – haemoglobin A1c, CVD – cardiovascular disease, HF – heart failure, eGFR – estimated glomerular filtration rate, DPP4-inhibitor – dipeptidyl peptidase 4 inhibitor, SGLT-2 
inhibitor – sodium/glucose co transporter 2 inhibitor.  
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Figure 1: PRISMA flow diagram of included trials.  
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Figure 2: Risk of MACE and each of its components  
For PIONEER 6, fatal and non-fatal MI and stroke was not available, hence numbers and estimates refer to non-fatal 
MI, and non-fatal stroke exclusively. 
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Figure 3: Cardiovascular outcome of GLP-1 receptor agonists for selected subgroups  
 
Higher baseline HbA1c” defined as: >7.5% in ELIXA, >8.0% in EXSCEL, >8.3% in LEADER, >8.5% in SUSTAIN-6, 
>8.0% in Harmony, >7.2% in REWIND and >8.5% in PIONEER 6. In REWIND, patients were divided by BMI>32 / 
BMI ≤32, and agegroups <66 / ≥66 years. In LEADER agegroups were <60/≥60 years. 
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Figure 4: All-cause mortality, heart failure hospitalization, and renal outcomes 
 
*not regarded statistically significant due to hierarchical statistical testing plan. 
§
number needed to harm. Data on renal 
outcomes were not available in Harmony Outcomes and PIONEER 6. The broader “composite renal outcome” 
consisted of development of macroalbuminuria, doubling of serum creatinine or ≥40% decline in eGFR, development of 
end-stage renal disease or death due to renal disease. The narrower “worsening of renal function” outcome was defined 
as either doubling of serum creatinine or ≥40% decline in eGFR. Exact definitions of renal outcomes are detailed in 
Appendix Table 2.   
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ABSTRACT 1 
Background: A variety ofSeveral glucagon-like peptide-1 (GLP-1) receptor agonists have been 2 
tested in clinical trials in patients with type 2 diabetes with different patient populations, 3 
cardiovascular outcomes and duration of follow-up. We planned a systematic review and meta-4 
analysis of these trials, examining cardiovascular death, atherothrombotic cardiovascular events, 5 
heart failure, and death from any cause, as well as renal and key safety outcomes.  6 
Methods: We pooled data from trials using albiglutide, dulaglutide, exenatide extended release, 7 
liraglutide, lixisenatide, liraglutide, and semaglutide in adult patients with type 2 diabetes reporting 8 
major adverse cardiovascular events (MACE) i.e. death from cardiovascular death, stroke or 9 
myocardial infarction. PubMed, Medline and the Cochrane central register of controlled trials were 10 
searched for eligible trials reporting major adverse cardiovascular events (MACE) i.e. 11 
cardiovascular death, stroke or myocardial infarction up to June 15, 2019. A meta-analysis was 12 
performed using a random-effects model to estimate overall hazard ratios (HR) for MACE, each of 13 
theits components of this composite, death from any cause, hospital admission for heart failure, 14 
renal outcomes and key safety outcomes (severe hypoglycaemia, pancreatitis and pancreatic 15 
cancer). We also examined MACE in several patient subgroups based on patient population 16 
(primary versus secondary prevention),, glycated haemoglobin concentration (“higher” versus 17 
“lower”), trial duration (shorter versus longer follow-up), treatment dosing interval (daily versus, 18 
weekly, reflecting duration of drug action) a and structural homology. (exendin 4-based versus 19 
GLP-1-based). 20 
ResultFindings: Of 27 publications screened, 7 trials using GLP-1 receptor agonists, with a total of 21 
56,006 patients, fulfilled the prespecified criteria and were included. Overall, GLP-1 receptor 22 
agonist treatment reduced MACE by 12% (HR 0.88; 95% CI 0.82, 0.94, p<0.001). There was no 23 
statistically significant heterogeneity across the subgroups examined.  24 
4 
 
 1 
GLP-1 receptor agonist treatment reduced all-cause mortality by 12% (0.88; 0.83, 0.95, p=0.001), 2 
hospital admission for heart failure by 9% (0.91; 0.83, 0.99, p=0.028) and a broad renal composite 3 
by 17% (0.83; 0.78, 0.89, p<0.001). There was no increase in risk of severe hypoglycaemia, 4 
pancreatitis or pancreatic cancer. any of the safety outcomes examined. 5 
ConclusionInterpretation: GLP-1 receptor agonists reduced  3-component MACE, its individual 6 
components, all-cause mortality,  and risk of hospitalization for heart failure and worsening renal 7 
function (due mainly to reduction in urinary albumin excretion) in patients with type 2 diabetes.   8 
This type of treatment also reduces the risk of worsening renal function (due mainly to reduction in 9 
urinary albumin reduction) and these benefits were obtained without anThere was no increase in 10 
risk of severe hypoglycaemia or pancreatic adverse effects.  11 
Funding: DP is supported by a University of Oxford BHF Centre of Research Excellence Senior 12 
Transition Fellowship (RE/13/1/30181). JJVMcM is supported by BHF Centre of Research 13 
Excellence award number RE/18/6/34217. 14 
Keywords: diabetes, GLP-1 receptor agonists, MACE, heart failure 15 
 16 
 17 
 18 
 19 
 20 
 21 
 22 
 23 
  24 
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RESEARCH IN CONTEXT 1 
Evidence before this study 2 
Glucagon-like peptide-1 (GLP-1) receptor agonists effectively decrease glycated haemoglobin (HbA1c) in 3 
patients with type 2 diabetes mellitus. A variety of agents of this class with differing structures and durations 4 
of action have been studied in randomised placebo-controlled trials of varying size and with different patient 5 
populations and effects on cardiovascular outcomes. In light of these differences, we conducted a meta-6 
analysis of all large placebo-controlled GLP-1 receptor agonist trials to obtain robust estimates on the effect 7 
of this class of agent on a range of cardiovascular and renal endpoints, and patient subgroups.  8 
Medline (via PubMed) and the Cochrane Controlled Register of Trials (up to 125 June 2019) were searched 9 
for trials comparing a GLP-1 receptor agonist to placebo in >500 patients and reporting a primary outcome 10 
including cardiovascular death, non-fatal myocardial infarction and non-fatal stroke using the search terms 11 
“glucagon-like peptide-1 receptor agonists”, “cardiovascular mortality”, “myocardial infarction”, “stroke” 12 
and “heart failure”, “exenatide”, “liraglutide”, “semaglutide”, “albiglutide”, “dulaglutide”, “placebo”, and 13 
“randomized clinical trial”. 7 trials were identified; ELIXA (lixisenatide), LEADER (liraglutide), SUSTAIN-14 
6 (semaglutide), EXSCEL (extended release exenatide), Harmony Outcomes (albiglutide), REWIND 15 
(dulaglutide) and PIONEER 6 (oral semaglutide).  16 
 17 
Added value of this study 18 
GLP-1 receptor agonists reduce all-cause mortality, the composite of cardiovascular death, myocardial 19 
infarction and stroke (MACE), each of the components of this outcome, hospital admission for heart failure 20 
and a composite renal outcome of worsening of estimated glomerular filtration rate (eGFR), end stage renal 21 
disease, death attributable to renal causes, or new onset macroalbuminuria (data not available in Harmony 22 
Outcomes and PIONEER 6 for the latter two outcomes). The benefit on MACE was consistent across all but 23 
one subgroup (with a suggestion of less effect of exendin 4 based compounds). The incidence of severe 24 
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hypoglycaemia, pancreatitis and pancreatic cancer did not differ between GLP-1 receptor agonist treatment 1 
and placebo. The present meta-analysis is the largest pooled study of the effect of GLP-1 RA on 2 
cardiovascular and renal outcomes in patients with type 2 diabetes mellitus. Furthermore, compared to 3 
previous meta-analyses, it includes a greater number of patients without established cardiovascular disease, a 4 
new agent within this class of glucose lowering agents (dulaglutide) and an oral formation of an agent 5 
previously only available as a subcutaneous injection (semaglutide).  6 
 7 
Implications of all the available evidence 8 
The cardioprotective effects of GLP-1 receptor agonists in  patients with and possibly without established 9 
cardiovascular disease and the reduction in risk of heart failure and worsening renal function represent an 10 
important treatment opportunity to reduce morbidity and mortality in patients with type 2 diabetes mellitus to 11 
reduce morbidity and mortality.  12 
 13 
 14 
  15 
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INTRODUCTION 1 
Prevention of non-fatal and fatal cardiovascular events is a key goal of the management of patients 2 
with type 2 diabetes mellitus (T2D).
1,2
  In addition to blood pressure and cholesterol-lowering 3 
therapies, two of the newer classes of anti-hyperglycaemic agents also reduce cardiovascular risk.  4 
One of these, the glucagon-like peptide-1 (GLP-1) receptor agonists, decrease glycated 5 
haemoglobin (HbA1c) by stimulating glucose-dependent insulin secretion and by reducing 6 
glucagon secretion, gastric emptying and appetite.
3,4
  GLP-1 receptor agonists also lead to modest 7 
improvements in lipids, reductions in blood pressure and weight, and carry a low risk of 8 
hypoglycaemia.  Agents in this class, however, differ in structure and duration of action and have 9 
been studied in trials of varying size and with different patient populations and in individual trials 10 
the effects on cardiovascular outcomes have not been consistent.
5-15
  In view of this we conducted a 11 
meta-analysis of all the large placebo-controlled GLP-1 receptor agonist trials, to obtain robust 12 
estimates of the effect of this class of agents on different cardiovascular endpoints and patient 13 
subgroups. We have also examined renal outcomes and key safety endpoints. Such a systematic 14 
review is helpful in supporting guideline recommendations on use of glucose lowering therapies to 15 
reduce macrovascular and renal outcomes in adults with type 2 diabetes.
1,2
 16 
 17 
  18 
8 
 
METHODS 1 
Search strategy and study selection: We identified published randomised placebo-controlled trials 2 
(RCTs) testing GLP-1 receptor agonists in patients with type 2 diabetes (Appendix Table 1). Both 3 
injectable and oral agents were included. We further restricted the search to trials with a primary 4 
outcome including cardiovascular death, non-fatal myocardial infarction and non-fatal stroke. 5 
Medline (via PubMed), and the Cochrane Controlled Register of Trials (Up to 15 June 2019) was 6 
searched with the search terms including “glucagon-like peptide-1 receptor agonists”, 7 
“cardiovascular mortality”, “myocardial infarction”, “stroke” and “heart failure”, “exenatide”, 8 
“liraglutide”, “semaglutide”, “albiglutide”, “dulaglutide”, “placebo”, and “randomized clinical 9 
trial”. We restricted our search to trials including >500 patients. Included trials were assessed for 10 
bias using the Cochrane Risk of Bias Tool (Appendix Table 2). A Preferred Reporting Items for 11 
Systematic Reviews and Meta-analyses (PRISMA) flow chart detailing the selection process is 12 
presented in Figure 1.  13 
Data extraction: Data were extracted by SLK and RR, with conflicts over study inclusion resolved 14 
by consensus.  15 
Selection of outcomes: Cardiovascular outcomes of interest were major adverse cardiovascular 16 
events (MACE), a composite outcome comprised of cardiovascular death, myocardial infarction 17 
and stroke, each of the components of this outcome, hospital admission for heart failure and death 18 
from any cause. Renal and safety outcomes were also examined. Two renal outcomes were 19 
examined, as reported previously: a narrower composite consisting of worsening of estimated 20 
glomerular filtration rate (eGFR), and a broader one which included end-stage kidney disease, death 21 
due to kidney disease and new onset macroalbuminuria (Appendix Table 13). The four key safety 22 
outcomes of interest were severe hypoglycaemia, retinopathy, pancreatitis and pancreatic cancer 23 
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(Appendix Table 24). We also examined thyroid cancer (Appendix Table 35). In all 7 trials, local 1 
investigators were encouraged to manage participants in accordance with local guidelines (and 2 
could use most non-study glucose lowering treatments as desired). In 6 of the 7 trials, the mean 3 
between-treatment group difference in HbA1c was in the range 0.3% and 0.7%. We compared 4 
treatment effect in the following subgroups: primary versus secondary prevention, higher versus 5 
lower baseline HbA1c concentration (see footnote to Figure 3 for details), longer versus shorter 6 
duration of follow-up, drug-dosing daily versus weekly, human GLP-1 homology, body mass index 7 
<30 versus ≥30, age <65 years versus ≥65 years, baseline eGFR <60 vs ≥60 mL/min/m2. All 8 
outcomes were adjudicated with the exception of severe hypoglycaemia, and event definitions for 9 
each trial are listed in the Appendix (Tables 1,3,4).appendix. 10 
 11 
Data analysis: Summary statistics from the individual trials included were used, as individual level 12 
data were not available. HRs and 95% CIs from the trial papers, supplementary appendix or 13 
secondary publications were used. Estimates from each study were combined by use of inverse 14 
variance-weighted averages of logarithmic hazard ratios (HR) in random-effects analysis. Inter-15 
study heterogeneity was assessed using the I
2 
index and Cochran´s Q test. I
2
 index values lower than 16 
25% indicated low, 26-50% moderate and more than 50% high degree of heterogeneity, and 17 
Cochran´s Q statistic p<0.05 were considered indicators for significant heterogeneity. Number 18 
needed to treat (NNT) was calculated using the method of Altman and Andersen, and median 19 
duration of follow-up was estimated by a weighted average.
16
. For subgroups without heterogeneity, 20 
we used overall estimates of treatment effects. The fragility index, the minimum number of events 21 
needing to change from a non-event to an event in order to render a significant result non-22 
significant, was calculated for 3-component MACE outcomes using the method described by Walsh 23 
et al. (Appendix Table 56).
17
 Interactions between treatment and subgroups were examined using a 24 
10 
 
test for heterogeneity, using p<0.1 as significant. All analyses were performed separately using 1 
Stata version 14 (Stata Corp. College Station, Texas, USA).  2 
 3 
Role of the funding source: The study was planned and conducted by members of the Metabolic 4 
and Diabetes Research Group and Heart Failure research Group at the University of Glasgow 5 
(KFD, PSJ, MCP, NS and JJVMcM), the Department of Cardiology, Rigshospitalet University 6 
Hospital, Copenhagen (SLK, RR, LK) and the Nuffield Department of Public Health at the 7 
University of Oxford (DP) using institutional funds. No external funder was involved in the study.  8 
 9 
10 
11 
 
RESULTS 1 
 2 
Trials included: Of 27 articles screened for eligibility, 7 trials with 56,006 patients were included 3 
in the meta-analysis (Figure 1). In order of reporting, these were: The Evaluation of Lixisenatide in 4 
Acute Coronary Syndrome (ELIXA), the Liraglutide Effect and Action in Diabetes: Evaluation of 5 
Cardiovascular Outcomes Results (LEADER), the preapproval Trial to Evaluate Cardiovascular and 6 
Other Long-term outcomes with Semaglutide in Subjects with Type 2 Diabetes (SUSTAIN-6), the 7 
Exenatide Study of Cardiovascular Event Lowering (EXSCEL), Albiglutide and cardiovascular 8 
outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes), 9 
Researching Cardiovascular Events With a Weekly Incretin in Diabetes (REWIND), and a trial 10 
investigating the Cardiovascular Safety of Oral Semaglutide in Subjects with Type 2 Diabetes 11 
(PIONEER 6).
6-14
 All included trials were assessed for bias using the Cochrane risk of bias tool. 12 
The trials were assessed as high quality with a low risk of bias (Supplementary appendix 13 
4Appendix, Table 2). The key trial and patient characteristics at baseline are presented in Tables 1 14 
and Appendix Table  21.  15 
Trial design and treatment: All trials were of substantial size (>3000 patients). ELIXA enrolled 16 
patients with a recent acute cardiovascular syndrome whereas all other trials included patients with 17 
stable cardiovascular disease, cardiovascular risk factors or both. All trials, except ELIXA, had 18 
MACE as the primary endpoint; in ELIXA an expanded composite including hospitalization for 19 
unstable angina was usedthe primary endpoint. Lixisenatide (ELIXA), liraglutide (LEADER), and 20 
oral semaglutide (PIONEER 6) were each administered daily, whereas the remaining GLP-1 21 
receptor agonists were administered once weekly. PIONEER 6 differed from the remaining trials in 22 
that semaglutide was taken orally, compared with subcutaneous administration of the treatments 23 
used in the remaining studies.  24 
12 
 
Patient characteristics: Mean age at baseline ranged from 60 years in ELIXA to 66 years in 1 
PIONEER 6 and REWIND. The highest proportion of women was included in REWIND (46% 2 
compared with between 31 and 39% in the remaining trials). The proportion of patients with 3 
established cardiovascular disease at baseline ranged from in 100% in ELIXA and Harmony 4 
Outcomes to 31% of those in REWIND (Table 12). Kidney function was similar across trials (with 5 
median estimated glomerular filtration rate ranging from 74 to 80 ml/min/m
2
). Median HbA1c was 6 
lowest in REWIND and ELIXA (7.1% and 7.7%, respectively) and highest, at 8.7%, in LEADER, 7 
SUSTAIN-6 and Harmony Outcomes. REWIND had the lowest proportional use of insulin at 8 
baseline (24% compared with 39-61% in remaining trials). The median length of follow-up ranged 9 
from 1.3 years in PIONEER 6 to 5.4 years in REWIND; the estimated median follow-up was 3.2 10 
years (Appendix Table 1). Treatment discontinuation and loss to follow-up is summarised in 11 
Appendix Table 67. 12 
Effect of GLP-1 receptor agonists on MACE and its components: In the pooled analysis, 13 
treatment with a GLP-1 receptor agonist led to a 12% relative risk reduction in MACE (HR 0.88; 14 
95% CI 0.82, 0.94; p<0.001) [Figure 2]. The NNT was 75 (95% CI 50, 151) over an estimated 15 
median follow-up of 3.2 years and the fragility index, overall, was 202 (Appendix Table 56). When 16 
assessing the components of the composite MACE endpoint separately, GLP-1 receptor agonist use 17 
led to a reduction in risk of death from cardiovascular causes (HR 0.88 95% CI 0.81, 0.96; 18 
p=0.001), fatal- or non-fatal stroke (HR 0.84; 95% CI 0.76, 0.93; p<0.001), and fatal or non-fatal 19 
MI (HR 0.91; 95% CI 0.84, 1.00; p=0.043) [Figure 2].  20 
Subgroup analyses for MACE: In subgroup analyses Tthere was no statistical heterogeneity 21 
between the effect of a GLP-1 receptor agonist in “primary prevention” patients (those without 22 
established cardiovascular disease) and those with cardiovascular disease at baseline: HR 0.95 (95% 23 
CI 0.83, 1.08) for “primary prevention” and 0.86 (0.79, 0.94) for “secondary prevention”,  24 
13 
 
respectively, p for interaction=0.22. Similarly, we found no heterogeneity for the effect of GLP-1 1 
receptor agonist therapy when examined by baseline HbA1c (“low” compared with “high” median 2 
HbA1c), shorter compared with longer trial follow-up (<3 years vs. ≥3 years median follow-up), 3 
drug dosing interval (daily compared with weekly dosing), reflecting duration of drug action. The 4 
one possible exception was the comparison of exendin 4-based compounds (lixisenatide and 5 
exenatide) and agents more homologous with human GLP-1 (all other drugs studied);  this analysis 6 
suggested heterogeneity: HR 0.95 (95% CI 0.85, 1.06) for exendin 4-based, compared with 0.84 7 
(0.79, 0.90) for GLP-1-based, respectively, p-value for interaction =0.06 (Figure 3). 8 
Death from any cause: Compared with placebo, treatment with a GLP-1 receptor agonist reduced 9 
the risk of death from any cause by 12% (HR 0.88; 95% CI 0.83, 0.95; p=0.001), giving a NNT of 10 
108 (77, 260) [Figure 4].   11 
Hospital admission for heart failure: The risk of HF hospitalization was also reduced in GLP-1 12 
receptor agonist treated patients, by 9% (HR 0.91; 95% CI 0.83, 0.99; p=0.028), giving a NNT of 13 
311 (164, 2797) [Figure 45]. 14 
Effect of GLP-1 receptor agonists on renal outcomes: Renal events were not available for 15 
Harmony Outcomes or PIONEER 6. Treatment with a GLP-1 receptor agonist reduced the broader 16 
composite renal outcome of worsening renal function, end-stage renal disease and renal death, 17 
including development of macroalbuminuria, by 17% (HR 0.83, 95% CI 0.78, 0.89) with a NNT of  18 
62 (48, 96). There was a 13% reduction (HR 0.87, 0.73, 1.03) in the narrower outcome of 19 
worsening renal function outcome of 13% (HR 0.87, 0.73, 1.03) which was of borderline statistical 20 
significance; the corresponding NNT was 245 (118, -1064) (Figure 64). 21 
Safety outcomes: The incidence of severe hypoglycaemia, pancreatitis and pancreatic cancer did 22 
not differ between GLP-1 receptor agonist treatment and placebo (Appendix Figure 17). The 23 
14 
 
incidence of retinopathy did not differ between GLP-1 receptor agonist treated and placebo treated 1 
patients, but this outcome was not defined consistently among the trials (Appendix Figure 1). Event 2 
ratesThe rate of thyroid carcinoma were was low and did not differ between the active treatment 3 
and placebo groups (Appendix Table 35).  4 
  5 
15 
 
DISCUSSION 1 
The present meta-analysis includes 13,084 (30%) more patients, 1394 (29%) more MACE 2 
endpoints, 1818 (95%) more renal events and approximately 56,000 more years of patient exposure 3 
than the largest prior study of this type.
18,19
 The present report also includes 6709 (95%) more 4 
“primary prevention” patients (i.e. with cardiovascular risk factors rather than established 5 
cardiovascular disease), one additional agent in the class i.e. dulaglutide with homology to human 6 
GLP-1 and a long duration of action, and a novel oral formulation of semaglutide which was 7 
administered by sub-cutaneous injection in a previous trial.  8 
 9 
Three-component MACE, the primary endpoint in 6 of the 7 trials, was reduced by 12%, reflecting 10 
a beneficial effect on death from cardiovascular causes (relative risk reduction 12%), as well as a 11 
reduction in risk of stroke (16% relative risk-reduction in fatal and non-fatal stroke).  The reduction 12 
in myocardial infarction (9% relative risk-reduction in fatal and non-fatal myocardial infarction) 13 
was less robust though directionally concordant. The NNT for MACE was 75 (95% CI 50, 151) 14 
over an estimated median duration of follow-up of 3.2 years. The relative risk reduction in MACE 15 
in a recent sodium-glucose co-transporter 2 (SGLT2) inhibitor meta-analysis was 11 (4-17)% and 16 
the NNT 97 (63, 266) over an estimated median follow-up of 3.3 years, although this comparison 17 
should be made cautiously as it does not take account of differences in the patient populations 18 
studied. and duration of follow-up. ,. The hazard ratio for death from any cause in GLP-1 receptor 19 
agonist trials was 0.88 (95% CI 0.83-0.95) and NNT 108 (77, 260); in the SGLT2 inhibitor meta-20 
analysis the corresponding HR was 0.85 (95% CI 0.78-0.93) and NNT 101 (69,216).
20
   21 
  22 
 23 
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We undertook several subgroup analyses to address the explanations proposed for the different 1 
effects on cardiovascular outcomes observed among the various GLP-1 receptor agonist trials. 2 
These include differences in the specific molecule tested, in the patients randomized, and in the 3 
duration of follow-up. Albiglutide, dulaglutide, liraglutide, and semaglutide are more similar, 4 
structurally, to native GLP-1 whereas exenatide and lixisenatide are based, structurally, on exendin-5 
4.
21,22
 Duration of treatment effect also differs markedly between the agents studied, although this 6 
does not reflect structural homology, with some GLP-1 receptor agonists of each type having a 7 
short pharmacologic half-life (e.g. lixisenatide 2-3 hours and liraglutide 12 hours) and others a long 8 
half-life (e.g. dulaglutide 120 hours and subcutaneous semaglutide 170 hours), or available as a 9 
sustained release formulation (exenatide), reflected in daily versus weekly dosing.
23
 The oral 10 
formulation of semaglutide used in PIONEER 6 required daily dosing. With the seven trials now 11 
available it was possible to examine whether these pharmacological characteristics, and their 12 
permutations, influence treatment efficacy. While duration of drug action did not seem to modify 13 
the treatment-effect, there was a suggestion of an interaction related to chemical structure, with a 14 
possibly smaller effect on MACE of agents based on exendin-4. This apparent interaction could be 15 
unduly influenced by ELIXA, which was unique in recruiting patients with a recent acute coronary 16 
syndrome (and also used a very short-acting agent, administered once daily), poor adherence in 17 
EXSCEL (40% permanent treatment discontinuation) or may be a chance finding. The ongoing 18 
Efpeglenatide on Cardiovascular Outcomes trail (AMPLITUDE-O - ClinicalTrials.gov unique 19 
identifier: NCT03496298), using a long-acting exendin-4 based GLP-I 1 receptor agonist in patients 20 
with established cardiovascular disease or cardiovascular risk factors will provide more evidence on 21 
this question. 22 
 23 
17 
 
The difference in patient population enrolled in the various GLP-1 receptor agonist trials has also 1 
been considered a potential explanation for the difference in outcomes among the studies.
24
 In 2 
particular, the lack of clear reduction in the primary MACE endpoint in EXSCEL has been 3 
attributed to the higher proportion of patients without established cardiovascular disease 4 
randomized in that trial, compared with the preceding GLP-1 receptor agonists trials. The inclusion 5 
of PIONEER 6 and, especially, REWIND allowed us to examine this question, with an almost 6 
doubling in the number of “primary-prevention” patients, overall, exposed to a GLP-1 receptor 7 
agonist, although even with this, the number of participants with MACE in this subgroup was less 8 
than a third of that in most other subgroups. Consequently, this analysis may still be under powered 9 
and, although there was no heterogeneity for the effect of GLP-1 receptor agonist treatment, the 10 
statistical test for interaction is weak. Therefore we cannot be certain that the relative risk reduction 11 
in “primary prevention” patients was the same as in “secondary prevention” patients and even if it 12 
was, the absolute risk reduction in the “primary prevention” population will be smaller, and the 13 
treatment likely to be less cost-effective, because individuals without established cardiovascular 14 
disease are at lower baseline risk than “secondary prevention” patients. These additional data may, 15 
therefore, not be sufficiently robust to challenge the new guideline recommendations only to use 16 
GLP-1 receptor agonists in patients with established cardiovascular disease.
1,2
 The inclusion of 17 
PIONEER-6 and, especially, REWIND allowed us to examine this question, with an almost 18 
doubling in the number of “primary-prevention” patients, overall, exposed to GLP-1 receptor 19 
agonists treatment. . We did not show any statistical heterogeneity of the effect of GLP-1 receptor 20 
agonist treatment on MACE according to whether patients had, or did not have, established 21 
cardiovascular disease at baseline. However, the number of patients with a major adverse 22 
cardiovascular event in the “primary prevention” prevention subgroup was less than half that in any 23 
other subgroup (and less than a third in most subgroups). Therefore, this subgroup may still be 24 
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under powered, although our findings do at least challenge the new guideline recommendations 1 
only to use GLP-1 receptor agonists in patients with established cardiovascular disease.
1,2
 However, 2 
even if the relative risk reduction with treatment is consistent in patients with and without 3 
established cardiovascular disease, the absolute risk reduction in the latter will be smaller and the 4 
treatment less cost-effective  5 
 6 
Duration of follow-up was a further potential explanation for difference discrepancy in trial 7 
outcomes, with, for example, the much shorter follow-up in ELIXA (median 2.1 years) than 8 
LEADER (median 3.8 years) highlighted as an important difference between the first two large 9 
outcome trials with a GLP-1 receptor agonist. However, duration of follow-up did not seem to 10 
modify the benefit of treatment on the composite MACE outcome.  11 
Two of the other subgroups merit discussion. The effect of GLP-1 receptor agonist treatment was 12 
consistent according to age and renal function. Because older age and lower eGFR were associated 13 
with higher rates of MACE, the absolute benefit was larger in these individuals. (as demonstrated 14 
by a smaller NNT).  15 
This updated meta-analysis also shows for the first time that treatment with a GLP-1 receptor 16 
agonist reduces the risk of heart failure hospitalization, although the reduction in risk was small in 17 
relative (9%, 95% CI 1-17%) and absolute (NNT 311; 95% CI 164, 2797) terms and was not 18 
statistically robust. This effect was also, clearly, much smaller than seen with SGLT2 inhibitors, 19 
which showed a relative risk reduction of 31 (21-39)% and a NNT of 100 (79, 147) over a similar 20 
median duration of follow-up (3.2 vs 3.3 years). Nevertheless, a GLP-1 receptor agonist may be an 21 
useful alternative in a patient with heart failure (or renal impairment) who cannot take a SGLT2 22 
inhibitor.
20
 The explanation for why GLP-1 receptor agonists should reduce this endpoint is not 23 
clear, especially as these agents has not demonstrated any benefit in trials in patients with 24 
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established heart failure with reduced ejection fraction.
25,26
 One possibility is that this favourable 1 
effect in the meta-analysis is secondary to reduction in myocardial infarction, a common precursor 2 
of heart failure. In this context, is notable that the largest reductions in heart failure were in the two 3 
trials (Harmony Outcomes and LEADER) with the greatest reduction in myocardial infarction. This 4 
hypothesis, however, needs further investigation, for example with examination of the time 5 
sequence of cardiovascular events in individual patients.  6 
 7 
It is clear, overall, that GLP-1 receptor agonists are cardioprotective agents. The time course of their 8 
effects, apparent in the individual trials, and the types of cardiovascular events prevented suggest 9 
that GLP-1 receptor agonists have primarily an anti-atherothrombotic effect.  This profile is distinct 10 
from the sodium-glucose co-transporter 2 (SGLT 2) inhibitors which exhibit an effect much more 11 
rapidly and which is more pronounced on heart failure, raising the possibility of therapeutic synergy 12 
from the combination of these two classes of drug.
27
   13 
 14 
This may also be true for renal outcomes. While we found that GLP-1 receptor agonists clearly 15 
reduced the risk of worsening of kidney function when assessed using a composite outcome driven 16 
by an increase in urinary albumin excretion, the benefit on a composite including a significant 17 
decline in eGFR (or increase in creatinine) was less clear, of borderline statistical significance and 18 
not as pronounced as seen with SGLT2 inhibitors.
18,27 
The relative risk reduction in the “harder” 19 
renal endpoint in the three large, broadly inclusive, SGLT2 inhibitor trials was 45 (36-52)% with a 20 
NNT of 79 (69, 99), compared with 13 (27-+3)% and 245 (118, -1064) in the present meta-21 
analysis.
18
 22 
 23 
20 
 
Lastly, this meta-analysis suggests that prior concerns about pancreatitis and pancreatic cancer with 1 
GLP-1 receptor agonists seem unfounded and there was also no increase in risk of severe 2 
hypoglycaemia. We also so no overall increase in adverse eye-outcomes, although these were 3 
inconsistently defined in the trials, a deficit that should be remedied in future studies. The outcomes 4 
reported did not require systematic eye examination and this too is required for a full understanding 5 
of the effect of any glucose-lowering therapy on eye health. A dedicated trial of this type is 6 
currently underway with semaglutide (FOCUS - ClinicalTrials.gov unique identifier: 7 
NCT03811561). Our study has other limitations, including lack of patient-level data, restriction of 8 
subgroup analyses to the primary 3-component MACE endpoint, and ability to examine only the 9 
secondary endpoints and adverse events of special interest reported by the investigators of the trials 10 
included. 11 
 12 
In conclusion, in this meta-analysis, we show that in patients with type 2 diabetes, GLP-1 receptor 13 
agonists reduced 3-component MACE, its individual components of, all-cause mortality and risk of 14 
hospitalization for heart failure.   Treatment with a GLP-1 receptor agonist also reduces the risk of 15 
worsening renal function, due mainly to a decrease in development of macroalbuminuria. These 16 
benefits were obtained without an increase in risk of severe hypoglycaemia, pancreatic adverse 17 
effects, or thyroid cancer. 18 
 19 
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Table 1: Study inclusion criteria, glycaemia management and outcomes 
 ELIXA 
n=6068 
LEADER 
n=9340 
SUSTAIN 6 
n=3297 
EXSCEL 
n=14752 
HARMONY 
n=9463 
REWIND 
n=9903 
PIONEER 6 
n=3183 
Drug studied  Lixisenatide Liraglutide Semaglutide Exenatide Albiglutide Dulaglutide Semaglutide 
Key inclusion 
criteria  
HbA1c 5.5-11.0%, 
ACS within 180 days; 
age≥30 years 
HbA1c≥7.0% age≥50 
years with 
CVD/HF/CKD or 
age≥60 years with ≥1 
CVD risk factor 
HbA1c≥7.0% age≥50 
years with 
CVD/HF/CKD or 
age≥60 years with ≥1 
CVD risk factor 
HbA1c 6.5-10.0% 
established CVD and 
primary prevention 
age≥18 years 
HbA1c≥7.0%, age 
≥40 years, established 
CVD 
HbA1c≤9.5%,  ≤2 
antidiabetic drugs 
age≥50/55/60 years 
with CVD/ subclinical 
vascular/ risk factors 
age≥50 years with 
CVD/HF/CKD or 
age≥60 years with ≥1 
CVD risk factor 
Key safety exclusion 
criteria 
Unexplained 
pancreatitis, multiple 
endocrine neoplasia 
syndrome 
Chronic or acute 
pancreatitis, multiple 
endocrine neoplasia 
syndrome. 
calcitonin≥50 ng/L 
Chronic or acute 
pancreatitis, multiple 
endocrine neoplasia 
syndrome. 
calcitonin≥50 ng/L 
Chronic or acute 
pancreatitis, multiple 
endocrine neoplasia 
syndrome. 
calcitonin≥40 ng/L 
eGFR<30 mL/min per 
1.73m
2
, pancreatitis, 
multiple endocrine 
neoplasia syndrome 
eGFR<15 mL/min per 
1.73m
2
, liver disease, 
pancreatitis, multiple 
endocrine neoplasia 
syndrome 
eGFR<30 mL/min per 
1.73m
2
, pancreatitis, 
multiple endocrine 
neoplasia syndrome 
Glycaemic 
management 
If screening 
HbA1c<8.5% 
downtitration of 
insulin or 
sulfonylurea. GLP-1 
RA  and DPP4-I 
prohibited 
If screening 
HbA1c<8.0% 
downtitration of 
insulin. dose 
escalation over 2 
weeks. GLP-1 RA and 
DPP4-I prohibited 
If screening 
HbA1c<8.0% 
downtitration of 
insulin. dose 
escalation over 2 
weeks. GLP-1 RA and 
DPP4-I prohibited 
At physicians´ 
discretion according 
to guidelines. . GLP-1 
prohibited but DPP4-I 
allowed  
At physician´s 
discretion according 
to local guidelines 
At physician´s 
discretion according 
to local guidelines  
 
At physician´s 
discretion according 
to local guidelines.  
DPP4-I prohibited 
Statistical analysis  Primary analysis 
simultaneous 
assessment of non-
inferiority and 
superiority  
Primary analysis non-
inferiority. 
Hierarchical testing 
for superiority, 
secondary CV 
endpoints 
Primary analysis non-
inferiority. Superiority 
testing was not pre-
specified 
Primary analysis non-
inferiority. 
Hierarchical testing 
for superiority, 
secondary CV 
endpoints 
Primary analysis non-
inferiority. Then 
secondary testing for 
superiority, secondary 
CV endpoints 
Primary outcome 
MACE, Secondary 
outcomes CV 
endpoints and 
microvascular 
composite 
Primary analysis non-
inferiority. Then 
secondary testing for 
superiority, secondary 
CV endpoints 
Median duration of 
follow-up, years 
2.1 3.8 2.1 3.2 1.6  5.4 1.3 
Primary outcome MACE-4 (non-inf) MACE-3 (non-inf) MACE-3 (non-inf) MACE-3 (superiority) MACE-3 (non-inf) MACE-3 (superiority) MACE-3 (non-inf) 
Participants with a 
primary outcome* 
792* 1302 254 1744 766 1257 137 
Event rate per 100 
py (active/placebo) 
6.3/6.2 3.4/3.9 3.2/4.4 3.7/4.0 4.6/5.9 2.4/2.7 2.9/3.7 
25 
 
*For ELIXA we used a 3-component MACE outcomes (without hospitalisation for unstable angina) similar to other trials. HbA1c – haemoglobin A1c, ACS – acute 
coronary syndrome, CVD -cardiovascular disease, HF – heart failure, CKD – chronic kidney disease, eGFR – estimated glomerular filtration rate, GLP-1 RA – 
glucagon like receptor 1 agonist, DPP4-I, dipeptidyl peptidase 4 inhibitors, MACE – major adverse cardiac events, UAH – unstable angina pectoris. 
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Table 1: Baseline characteristics and use of glucose lowering agents across trials 
 ELIXA 
n=6068 
LEADER 
n=9340 
SUSTAIN- 6 
n=3297 
EXSCEL 
n=14752 
HARMONY 
n=9463 
REWIND 
n=9903 
PIONEER 6 
n=3183 
Drug studied  Lixisenatide Liraglutide Semaglutide Exenatide Albiglutide Dulaglutide Semaglutide 
Structural basis Exendin-4 based Human GLP-1 
based 
Human GLP-1 
based 
Exendin-4 based Human GLP-1 
based 
Human GLP-1 
based 
Human GLP-1 
based 
Administration route subcutaneous subcutaneous subcutaneous subcutaneous subcutaneous subcutaneous oral 
Dose 20 ug/day 1.8 mg/day 0.5 or 1 mg/week 2 mg/week 30 or 50 mg/week 1.5 mg/week 14 mg/day 
Age, mean – years  60±10 64±7 65±7 62±9 64±7 66±7 66±7 
Female sex, no. (%) 1861 (31%) 3337 (36%) 1295 (39%) 5603 (38%) 2894 (31%) 4589 (46%) 1007 (32%) 
BMI (kg/m
2
) 30.1±5.6 32.5±6.3 32.8±6.2 32.7±6.4 32.3±5.9 32.3±5.7 32.3±6.5 
Caucasian 4576 (75%) 7238 (78%) 2736 (83%) 11175 (76%) 6583 (70%) 7498 (76%) 2300 (72%) 
Diabetes duration, years 9.2±8.2 12.8±8.0 13.9±8.1 13.1±8.3 14.2±8.8 10.6±7.2 14.9±8.5 
HbA1c (%) 7.7±1.3 8.7±1.6 8.7±1.5 8.1±1.0 8.7±1.5 7.3±1.1 8.2±1.6 
Proportion with CVD 6068 (100%) 7598 (81%) 2735 (83%) 11175 (76%) 6678 (71%) 3114 (31%) 2692 (85%) 
Proportion with HF 1358 (22%) 1667 (18%) 777 (24%) 2389 (16%) 1922 (20%) 852 (9%) 388 (12%) 
Systolic blood pressure 
(mmHg) 
129±17 136±18 136±17 135±17 135±17 137±17 136±18 
eGFR, mL/min per 1.73 m
2 
78±21 80 (SD not given) 80 (61, 92) 77 (61,92) 79±25 75±24  74±21 
Glucose lowering agents. (%)        
Insulin  2374 (39%) 4159 (45%) 1913 (58%) 6838 (46%) 5597 (59%) 2398 (24%) 1943 (61%) 
Biguanides 4021 (66%) 7136 (76%) 2414 (73%) 11295 (77%) 7970 (84%) 8016 (81%) 2437 (77%) 
Sulfonylurea 2004 (33%) 4721 (51%) 1410 (43%) 5401 (37%) 2725 (29%) 5644 (57%) 1007 (32%) 
Thiazolidinedione 95 (2%) 573 (6%) 76 (2%) 579 (4%) 194 (2%) 168 (2%) N/A 
DPP4-inhibitor NA 6 (<1%) 5 (<1%) 2203 (15%) 1437 (15%) 88 (1%) 0 
SGLT2 inhibitor NA NA 5 (<1%) 77 (1%) 575 (6%) 12 (0%) 301 (10%) 
 BMI – body mass index, HbA1c – haemoglobin A1c, CVD – cardiovascular disease, HF – heart failure, eGFR – estimated glomerular filtration rate, DPP4-inhibitor – dipeptidyl peptidase 4 inhibitor, SGLT-2 
inhibitor – sodium/glucose co transporter 2 inhibitor.  
27 
 
Figure 1: PRISMA flow diagram of included trials.  
 
 
 
 
 
 
 
 
 
 
 
 
Records identified with  
pre-defined search strategy  
(n=182) 
  
Records screened 
(n=27) 
  
Full-text assessed for eligibility 
(n=19) 
  
Excluded with reasons  
article reporting non-
CV outcomes (n=1) 
Subgroup analysis or 
design paper (n=8) 
Duplication (n=3)  
  
Studies included in qualitative 
analysis 
(n=7)    
Studies included in quantitative 
analysis (meta-analysis) 
(n=7) 
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Figure 2: Risk of MACE and each of its components  
For PIONEER 6, fatal and non-fatal MI and stroke was not available, hence numbers and estimates refer to non-fatal 
MI, and non-fatal stroke exclusively. 
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Figure 3: Cardiovascular outcome of GLP-1 receptor agonists for selected subgroups  
 
Higher baseline HbA1c” defined as: >7.5% in ELIXA, >8.0% in EXSCEL, >8.3% in LEADER, >8.5% in SUSTAIN-6, 
>8.0% in Harmony, >7.2% in REWIND and >8.5% in PIONEER 6. In REWIND, patients were divided by BMI>32 / 
BMI ≤32, and agegroups <66 / ≥66 years. In LEADER agegroups were <60/≥60 years. 
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Figure 4: All-cause mortality, heart failure hospitalization, and renal outcomes 
 
*not regarded statistically significant due to hierarchical statistical testing plan. 
§
number needed to harm. Data on renal 
outcomes were not available in Harmony Outcomes and PIONEER 6. The broader “composite renal outcome” 
consisted of development of macroalbuminuria, doubling of serum creatinine or ≥40% decline in eGFR, development of 
end-stage renal disease or death due to renal disease. The narrower “worsening of renal function” outcome was defined 
as either doubling of serum creatinine or ≥40% decline in eGFR. Exact definitions of renal outcomes are detailed in 
Appendix Table 2.   
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*not regarded statistically significant due to hierarchical statistical testing plan 
Figure 5: Heart failure hospitalization 
 
Figure 6: Renal outcomes 
 
Data on renal outcomes were not available in Harmony Outcomes and PIONEER 6. The broader “composite renal 
outcome” consisted of development of macroalbuminuria, doubling of serum creatinine or ≥40% decline in eGFR, 
development of end-stage renal disease or death due to renal disease. The narrower “worsening of renal function” 
outcome was defined as either doubling of serum creatinine or ≥40% decline in eGFR. Exact definitions of renal 
outcomes are detailed in Appendix Table 1. * number needed to harm 
 
Figure 7: Safety outcomes 
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For definitions of safety outcomes, please see Appendix Table 2. The definition of severe hypoglyacemia in all trials 
included clinical symptoms and the need for help from another person for treatment. SUSTAIN-6 also included 
symptomatic hypoglycemia as confirmed on plasma glucose testing (<3.1 mmol per litre [56 mg per deciliter] 
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usually ask that authors of research papers return their revised manuscript within 4-5 working days. 
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helpful to tabulate your responses with columns labelled (left to right) as follows: Reviewer 
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Neil Bennet 
--------------------------------------------- 
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Email: neil.bennet@lancet.com 
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Thank you – we hope our responses, provided below, and our revised manuscript is now 
satisfactory. We think it is definitely improved from the original and represents a fair an 
balanced update on field. 
 
EDITORS' SPECIFIC POINTS: 
 
*In addition to responding to the re-reviewers' comments, we require authors to respond to the 
general editorial comments listed below - we require responses to each of these points individually, 
to ensure all have been addressed. For example, as detailed in these general points, there is a limit 
on the number of non-text items (figures and tables) of 5-6: currently there are 9 such items in the 
paper. As such we need the authors to attempt to reduce this number, either by combining certain 
figures with similar layout, or by moving certain items to a separate appendix Word file (we would 
suggest the latter for table 1, and possibly figure 1 if necessary). Additionally, as detailed in the 
general editorial points, we require the figures (excluding any moved to an appendix file) to be 
supplied in an editable format. To ensure that the revised paper meets these and other 
requirements necessary for acceptance, please ensure that you go through and respond to all the 
points listed. 
*Reply to Reviewers Comments
 
We have replied to each point, individually, as requested. We have reduced the number of non-
text items to 5, as requested. We have complied with the general editorial points. 
 
*Based on the re-review comments from Reviewer #6, some further toning down may be required 
with respect to the subgroup analysis. This may also require some more detailed results reporting in 
the abstract (eg, so that readers of the abstract can see the actual HRs for subgroups (eg, primary 
and secondary prevention), as well as heterogeneity p values, with carefully worded interpretation. 
 
We have tried to address the somewhat conflicting comments of Reviewers #1 and #6 in our 
revised manuscript. Specifically, we have provided an estimated median follow-up for the NNTs 
and removed NNTs (based on the overall relative risk reduction) from the subgroup figure. We 
think it is best to simply state in the abstract that “There was no statistically significant 
heterogeneity across the subgroups examined.” To just show the primary vs. secondary 
prevention subgroup in the abstract would look rather strange. Alternatively, to include all 
subgroups would exceed the word limit, considerably. The most abbreviated way of describing 
these we could come up with was: “Overall, there was no statistically significant heterogeneity 
across the subgroups examined: HR for MACE in patients with a history of cardiovascular 
disease: yes 0.86 (95% CI 0.79, 0.94), no 0.95 (0.83, 1.08), (interaction p=0.22); glycated 
haemoglobin level: higher 0.85 (0.78, 0.92), lower 0.89 (0.83,0.96), (p=0.41); trial duration: 
shorter 0.84 (0.71,0.99), longer 0.89 (0.84,0.94), (p=0.52); dosing: daily 0.92 (0.80,1.05), weekly 
0.85 (0.78,0.93) (p=0.34); GLP-1 homology: yes 0.84 (0.79,0.90), no 0.95 (0.85,1.06), (p=0.06); 
body mass index: lower 0.87 (0.77,0.98), higher 0.87 (0.82,0.93), (p=1.00); age: younger 0.85 
(0.72,0.99), older 0.87 (0.81,0.93) (p=0.79); renal function: better 0.88 (0.76,1.03), worse 0.85 
(0.76,0.96), (p=0.72).” That is a total of 98 words. We think simply saying “There was no 
statistically significant heterogeneity across the subgroups examined.” is best – it is succinct and 
accurate. 
 
*We believe the title would read better as "Cardiovascular, mortality, and renal outcomes with 
glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes: a systematic review and 
meta-analysis of randomised trials" [NOTE: you can of course amend this as needed, eg, if you do 
not think it is appropriate to list these three groups of outcomes; structurally though, it is best to 
mention the outcomes analyses first, as in this suggestion] 
 
We have amended the title, as suggested. 
 
 
REVIEWERS' COMMENTS:  
 
Reviewer #1: The main changes to the manuscript since the previous review are that the authors 
have toned down their comments regarding GLP-1R agonists in primary prevention and added 
numbers needed to treat to the article.  
 
In their discussion of the lack of any statistical differences (page 16 lines 1-14), they seem to have 
the right idea but there are a lot of negatives ("did not show", "However", "although", and 
"however" in consecutive sentences) making it hard to fully understand. Perhaps best to focus on 
what is clear: i) they do not cause notable cardiovascular harm in primary prevention and may 
reduce risk; ii) the absolute benefit is likely smaller in primary than secondary prevention, largely 
because absolute risk is higher in secondary prevention; iii) even when combining the current set of 
trials there is a lack of power to accurately determine if there is a beneficial effect if one restricts to 
primary prevention populations.  
 
We have rewritten the relevant section of the Discussion in keeping with the Reviewer’s 
suggestion. It now says: 
 
“The inclusion of PIONEER 6 and, especially, REWIND allowed us to examine this question, with 
an almost doubling in the number of “primary-prevention” patients, overall, exposed to a GLP-1 
receptor agonist, although even with this, the number of participants with MACE in this subgroup 
was less than a third of that in most other subgroups. Consequently, this analysis may still be under 
powered and, although there was no heterogeneity for the effect of GLP-1 receptor agonist 
treatment, the statistical test for interaction is weak. Therefore we cannot be certain that the 
relative risk reduction in “primary prevention” patients was the same as in “secondary prevention” 
patients and even if it was, the absolute risk reduction in the “primary prevention” population will 
be smaller, and the treatment likely to be less cost-effective, because individuals without established 
cardiovascular disease are at lower baseline risk than “secondary prevention” patients. These 
additional data may, therefore, not be sufficiently robust to challenge the new guideline 
recommendations only to use GLP-1 receptor agonists in patients with established cardiovascular 
disease.” 
 
Their analyses of NNT suffer from two problems:  
i) they should give some indication of a time frame over which the NNT is relevant, e.g. perhaps the 
median/mean follow-up time. As the treatment gradually accrues cardiovascular benefit over time 
an NNT without a time reference is effectively meaningless (even if they have been published for 
SGLT2is). I realise some assumptions or back-of-the-envelope calculations may be required to give 
an approximate time-frame, but that is better than having a statistic which is largely meaningless.  
 
We agree and had written caveats stating this when originally asked by another Reviewer to 
add NNTs. We have added an estimated median follow-up, as suggested – this was 3.2 years. On 
balance, we think even with their limitations, the NNTs do succeed in making the point we 
believe the Reviewer who requested them wished to make – that the absolute treatment effects 
with these drugs are relatively modest. However, we would be happy to remove NNTs if that is 
the Editor’s preference. 
 
ii) In Figures 3 they present NNT calculated using an "overall" hazard ratio, next to subgroup hazard 
ratios. I think this is misleading as there is a reasonable expectation that the HR and NNT in the same 
row of the Figure relate to one another and would have been calculated on the same set of data. So I 
suggest they are (actually I feel quite strongly that these should be) removed from this particular 
figure (e.g. as they have done for individual trials with differing follow-up durations in other figures 
where the NNT likewise would have been misleading).  
 
We have removed NNTs for subgroups from the figure. 
 
Reviewer #4: Thank you for addressing all issues raised including providing NNTs. In aggregate, I feel 
the manuscript has improved considerably and gives novel and practically relevant information. 
 
Thank you. 
 
Reviewer #6: Manuscript re-reviewed without access to a track changes version. This version mostly 
addresses the concerns expressed in my original review. I do find the manuscript marginal in priority 
because it offers almost no insights not already provided by the included trials. I still think the 
authors over-emphasize the potential role of GLP-1 agonists in primary prevention. Although there is 
no "statistical heterogeneity" the analysis is severely underpowered for this assessment. I must 
point out that the HR in the primary prevention population is 0.95 with an upper CI of 1.08. The lack 
of an interaction P value likely represents a lack of power. In general the authors over-emphasize 
subgroup analyses which leads to potentially misleading conclusions. The subgroup "human GLP-1 
homology" is HIGHLY confounded by differences in drug pharmacokinetics UNRELATED to homology. 
I would request that the authors go further in explaining that these analyses are potentially 
unreliable. In the words of a very prominent statistician: "let me study enough subgroups and I'll 
show you anything you want." 
 
We have “toned down” our comments about primary prevention in response to the Reviewers’ 
and Editor’s comments (see above).  
 
Regarding "human GLP-1 homology", we examined a modest number of subgroups (eight in 
total) and, in fact, some of these were added at the request of the Reviewers. We think we have 
made it very clear in the text of the Discussion that this is a potentially confounded subgroup (as 
indeed is any univariate subgroup). However, it does address one suggestion put forward to 
explain apparent differences between the trials and therefore is of interest. We believe that we 
have both addressed the question and given a balanced and detailed discussion of the answer, 
including the complexities of its interpretation. 
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3-component   
MACE 
GLP-1 receptor 
agonist n/N (%) 
Placebo 
n/N (%) 
 
Hazard ratio 
(95% CI) 
NNT 
(95% CI) 
P-value 
ELIXA 400/3034 (13%) 392/3034 (13%)  1.02 (0.89-1.17)  0.78 
EXSCEL 839/7356 (11%) 905/7396 (12%)  0.91 (0.83-1.00)  0.061 
LEADER 608/4668 (13%) 694/4672 (15%)  0.87 (0.78-0.97)  0.015 
SUSTAIN-6 108/1648 (7%) 146/1649 (9%)  0.74 (0.58-0.95)  0.016 
Harmony 338/4731 (7%) 428/4732 (9%)  0.78 (0.68-0.90)  <0.001 
REWIND 594/4949 (12%) 663/4952 (13%)  0.88 (0.79-0.99)  0.026 
PIONEER 6 61/1591 (4%) 76/1592 (5%)  0.79 (0.57-1.11)  0.17 
Overall 2948/27977 (11%) 3304/28027 (12%)  0.88 (0.82-0.94) 75 (50-151) <0.001 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure data for submission
Cardiovascular death GLP-1 receptor 
agonist n/N (%) 
Placebo 
n/N (%) 
 
Hazard ratio  
(95% CI) 
NNT 
(95% CI) 
P-value 
ELIXA 156/3034 (5%) 158/3034 (5%)  0.98 (0.78-1.22)  0.85 
EXSCEL 340/7356 (5%) 383/7396 (5%)  0.88 (0.76-1.02)  0.096 
LEADER 219/4668 (5%) 278/4672 (6%)  0.78 (0.66-0.93)  0.007 
SUSTAIN-6 44/1648 (3%) 46/1649 (3%)  0.98 (0.65-1.48)  0.92 
Harmony 122/4731 (3%) 130/4732 (3%)  0.93 (0.73-1.19)  0.58 
REWIND 317/4949 (6%) 346/4952 (7%)  0.91 (0.78-1.06)  0.18 
PIONEER 6 15/1591 (1%) 30/1592 (2%)  0.49 (0.27-0.92)  0.021 
Overall 1277/27977 (5%) 1471/28027 (5%)  0.88 (0.81-0.96) 163 (103-489) 0.003 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fatal – and non-fatal 
MI 
GLP-1 receptor 
agonist n/N (%) 
Placebo 
n/N (%) 
 
Hazard ratio  
(95% CI) 
NNT  
(95% CI) 
P-value 
ELIXA 270/3034 (9%) 261/3034 (9%)  1.03 (0.87-1.22)  0.71 
EXSCEL 483/7356 (7%) 493/7396 (7%)  0.97 (0.85-1.10)  0.62 
LEADER 292/4668 (6%) 339/4672 (7%)  0.86 (0.73-1.00)  0.046 
SUSTAIN-6 54/1648 (3%) 67/1649 (4%)  0.81 (0.57-1.16)  0.26 
Harmony 181/4731 (4%) 240/4732 (5%)  0.75 (0.61-0.90)  0.003 
REWIND 223/4949 (5%) 231/4952 (5%)  0.96 (0.79-1.15)  0.63 
PIONEER 6 37/1591 (2%) 31/1592 (2%)  1.18 (0.73-1.90)  0.49 
Overall 1540/27977 (6%) 1662/28027 (6%)  0.91 (0.84-1.00) 193 (109-na)  0.043 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fatal and non-fatal 
stroke 
GLP-1 receptor 
agonist n/N (%) 
Placebo 
n/N (%) 
 
Hazard ratio 
(95% CI) 
NNT  
(95% CI)  
P-value 
ELIXA 67/3034 (2%) 60/3034 (2%)  1.12 (0.79-1.58)  0.54 
EXSCEL 187/7356 (3%) 218/7396 (3%)  0.85 (0.70-1.03)  0.095 
LEADER 173/4668 (4%) 199/4672 (4%)  0.86 (0.71-1.06)  0.16 
SUSTAIN-6 30/1648 (2%) 46/1649 (3%)  0.65 (0.41-1.03)  0.066 
Harmony 94/4731 (2%) 108/4732 (2%)  0.86 (0.66-1.14)  0.30 
REWIND 158/4949 (3%) 205/4952 (4%)  0.76 (0.62-0.94)  0.01 
PIONEER 6 12/1591 (1%) 16/1592 (1%)  0.74 (0.35-1.57)  0.43 
Overall 721/27977 (3%) 852/28027 (3%)  0.84 (0.76-0.93) 209 (139-477) <0.001 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Heart failure 
hospitalization 
GLP-1 receptor 
agonist n/N (%) 
Placebo 
n/N (%) 
 
Hazard ratio 
(95% CI) 
NNT 
(95%CI) 
P-value 
ELIXA 122/3034 (4%) 127/3034 (4%)  0.96 (0.75-1.23)  0.75 
EXSCEL 219/7356 (3%) 231/7396 (3%)  0.94 (0.78-1.13)  0.51 
LEADER 218/4668 (5%) 248/4672 (5%)  0.87 (0.73-1.05)  0.14 
SUSTAIN-6 59/1648 (4%) 54/1649 (3%)  1.11 (0.77-1.61)  0.57 
Harmony 79/4731 (2%) 111/4732 (2%)  0.71 (0.53-0.94)  <0.01 
REWIND 213/4949 (4%) 226/4952 (5%)  0.93 (0.77-1.12)  0.46 
PIONEER 6 21/1591 (1%) 24/1592 (2%)  0.86 (0.48-1.44)  0.59 
Overall 931/27977 (3%) 1021/28027 (4%)  0.91 (0.83-0.99) 311 (164-2797)  0.028 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
All-cause mortality GLP-1 receptor 
agonist n/N (%) 
Placebo 
n/N (%) 
 
Hazard ratio 
 (95% CI) 
NNT 
 (95% CI)  
P-value 
ELIXA 211/3034 (7%) 223/3034 (7%)  0.94 (0.78-1.13)  0.50 
EXSCEL 507/7356 (7%) 584/7396 (8%)  0.86 (0.77-0.97)  0.016
§
 
LEADER 381/4668 (8%) 447/4672 (10%)  0.85 (0.74-0.97)  0.02 
SUSTAIN-6 62/1648 (4%) 60/1649 (4%)  1.05 (0.74-1.50)  0.79 
Harmony 196/4731 (4%) 295/4732 (4%)  0.95 (0.79-1.16)  0.64 
REWIND 536/4949 (11%) 592/4952 (12%)  0.90 (0.80-1.01)  0.067 
PIONEER 6 23/1591 (1%) 45/1592 (3%)  0.51 (0.31-0.84)  0.008 
Overall 1916/27977 (7%) 2246/28027 (8%)  0.88 (0.83-0.95) 108 (77-260) 0.001 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
MACE Subgroups GLP-1 receptor 
agonist n/N (%) 
Placebo 
n/N (%) 
 
Hazard ratio (95% CI) P-value for 
inter-action 
 History of cardiovascular disease    0.22 
     Yes 2431/21253 (11%) 2755/21202 (13%)  0.86 (0.79-0.94)  
     No 480/6428 (7%) 518/6555 (8%)  0.95 (0.83-1.08)  
Baseline HbA1c concentration    0.41 
     Higher 1645/14508 (11%) 1865/14296 (13%)  0.85 (0.78-0.92)  
     Lower 1300/13004 (10%) 1442/13664 (11%)  0.89 (0.83-0.96)  
Median duration of follow-up    0.52 
     ≤3 years 907/11004 (8%) 1042/11007 (9%)  0.84 (0.71-0.99)  
     >3 years 2041/16973 (12%) 2262/17020 (13%)  0.89 (0.84-0.94)  
Drug dosing     0.34 
     Daily 1069/9293 (12%) 1162/9298 (12%)  0.92 (0.80-1.05)  
     Weekly 1879/18684 (10%) 2142/18729 (11%)  0.85 (0.78-0.93)  
Human GLP-1 homology    0.06 
     Yes 1709/17587 (10%) 2007/17597 (11%)  0.84 (0.79-0.90)  
     No 1239/10390 (12%) 1297/10430 (12%)  0.95 (0.85-1.06)  
Body mass index, kg/m
2 
   1.00 
     <30* 1254/11752 (11%) 1403/11904 (12%)  0.87 (0.77-0.98)  
     ≥30 1679/16116 (10%) 1892/16011 (12%)  0.87 (0.82-0.93)  
Age     0.79 
     <65 years 1249/14195 (9%) 1346/13948 (10%)  0.85 (0.72-0.99)  
     ≥65 years 1705/13782 (12%) 1965/14079 (14%)  0.87 (0.81-0.93)  
Baseline eGFR, mL/min/m
2 
   0.72 
     <60  769/5341 (14%) 875/5432 (16%)   0.88 (0.76-1.03)  
     ≥60 1578/17653 (9%) 1773/17598 (10%)  0.85 (0.76-0.96)  
Overall 2948/27977 (11%) 3304/28027 (12%)  0.88 (0.82-0.94)  
 
 
 
 
 
 
Renal outcomes GLP-1 receptor 
agonist n/N (%) 
Placebo 
n/N (%) 
 
Hazard ratio  
(95% CI) 
NNT 
(95% CI) 
P-value 
Composite renal outcome including macroalbuminuria     
ELIXA 172/2639 (6%) 203/2647 (6%)  0.84 (0.68-1.02)  0.083 
EXSCEL 366/6256 (6%) 407/6222 (7%)  0.88 (0.76-1.01)  0.065 
LEADER 268/4668 (6%) 337/4672 (7%)  0.78 (0.67-0.92)  0.003 
SUSTAIN-6 62/1648 (4%) 100/1649 (6%)  0.64 (0.46-0.88)  0.006 
REWIND 848/4949 (17%) 970/4952 (20%)  0.85 (0.77-0.93)  <0.001 
Overall 1716/20160 (9%) 2017/20142 (10%)  0.83 (0.78-0.89)  62 (48-96) <0.001 
       
Worsening of renal function     
ELIXA 35/3032 (1%) 41/3031 (1%)  1.16 (0.74-1.83)  0.513 
EXSCEL 246/6456 (4%) 273/6458 (4%)  0.88 (0.74-1.05)  0.164 
LEADER 87/4668 (2%) 97/4672 (2%)  0.89 (0.67-1.19)  0.43 
SUSTAIN-6 18/1648 (1%) 14/1649 (1%)  1.28 (0.64-2.58)  0.48 
REWIND 169/4949 (3%) 237/4952 (5%)  0.70 (0.57-0.85)  <0.001 
Overall 555/20753(3%) 662/20762 (3%)  0.87 (0.73-1.03) 245 (118-1064*) 0.098 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Severe hypoglycaemia GLP-1 receptor 
agonist n/N (%) 
Placebo 
n/N (%) 
 
Odds ratio 
(95% CI) 
P-value 
ELIXA 14/3034 (<1%) 24/3034 (1%)  0.58 (0.30-1.13) 0.11 
EXSCEL 247/7356 (3%) 219/7396 (3%)  1.14 (0.95-1.37) 0.17 
LEADER 114/4668 (2%) 153/4672 (3%)  0.74 (0.58-0.95) 0.016 
SUSTAIN-6 369/1648 (22%) 350/1649 (21%)  1.07 (0.91-1.26) 0.42 
Harmony 31/4731 (1%) 55/4732 (1%)  0.56 (0.36-0.87) 0.009 
REWIND 64/4949 (1%) 74/4952 (2%)  0.86 (0.62-1.21) 0.38 
PIONEER 6 23/1591 (1%) 13/1592 (1%)  1.78 (0.90-3.53) 0.32 
Overall 
  
 0.90 (0.73-1.12) 0.34 
      
    
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Pancreatitis GLP-1 receptor 
agonist n/N (%) 
Placebo 
n/N (%) 
 
Odds ratio 
(95% CI) 
P-value 
ELIXA 5/3034 (<1%) 8/3034 (<1%)  0.62 (0.20-1.91) 0.41 
EXSCEL 26/7356 (<1%) 22/7396 (<1%)  1.19 (0.67-2.10) 0.55 
LEADER 18/4668 (<1%) 23/4672 (<1%)  0.78 (0.42-1.45) 0.44 
SUSTAIN-6 9/1648 (1%) 12/1649 (1%)  0.75 (0.32-1.78) 0.51 
Harmony 10/4731 (<1%) 7/4732 (<1%)  1.43 (0.54-3.75) 0.46 
REWIND 23/4949 (1%) 13/4952 (<1%)  1.77 (0.90-3.51) 0.11 
PIONEER 6 1/1591 (<1%) 3/1592 (<1%)  0.25 (0.03-2.24) 0.20 
Overall 
  
 1.03 (0.74-1.42) 0.86 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Pancreatic cancer GLP-1 receptor 
agonist n/N (%) 
Placebo 
n/N (%) 
 
Odds ratio 
(95% CI) 
P-value 
ELIXA 3/3034 (<1%) 9/3034 (<1%)  0.33 (0.09-1.23) 0.50 
EXSCEL 15/7356 (<1%) 16/7396 (<1%)  0.94 (0.47-1.91 0.87 
LEADER 13/4668 (<1%) 5/4672 (<1%)  2.61 (0.93-7.32) 0.069 
SUSTAIN-6 1/1648 (<1%) 4/1649 (<1%)  0.25 (0.03-2.24) 0.22 
Harmony 6/4731 (<1%) 5/4715 (<1%)  0.95 (0.79-1.16) 0.64 
REWIND 19/4949 (<1%) 12/4952 (<1%)  1.59 (0.77-3.27) 0.22 
PIONEER 6 na na  na na 
Overall 
  
 1.03 (0.67-1.58) 0.90 
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